High TP53 glioma samples were more sensitive to vorinostat, elesclomol, gefitinib, AICAR, axitinib, and bosutinib.<h4>Conclusion</h4>The TP53 score based on the P53 signaling pathway can describe the heterogeneity of glioma samples and distinguish different immune microenvironment characteristics and prognostic features. Here, TP53 is linked to central nervous system cancer.